Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · IEX Real-Time Price · USD
0.900
-0.027 (-2.94%)
At close: Jun 28, 2022 4:00 PM
0.925
+0.025 (2.789%)
After-hours:
Jun 28, 2022 7:55 PM EDT
Company Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders.
Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's.
The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jun 15, 2021 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 3 |
Contact Details
Address:
3802 Spectrum Blvd, Tampa, Florida 33612 United States | |
| Phone | 844 722 6333 |
| Website | alzamend.com |
Stock Details
| Ticker Symbol | ALZN |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | US Dollars |
| IPO Price | $5.00 |
| CIK Code | 1677077 |
| ISIN Number | US02262M3088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephan Jackman | Chief Executive Officer and Director |
| Henry C. W. Nisser Esq. | Executive Vice President, General Counsel and Director |
| Kenneth S. Cragun CPA | Senior Vice President of Finance |
| Milton Charles Ault III | Founder and Chairman Emeritus |
| Lien T. Escalona | Chief Financial Officer |
| David J. Katzoff | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2022 | 8-K | Current report |
| Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 15, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 9, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 8, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 6, 2022 | 8-K | Current report |
| Jun 3, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 31, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 26, 2022 | 4 | Statement of changes in beneficial ownership of securities |